The company’s software-as-a-service and sequencing and molecular analysis revenues grew, and the firm narrowed its loss from a year ago.
The company said 677 of its GPS Cancer commercial tests were ordered in Q1 2018, up from 606 in Q4 2017.
CEO Patrick Soon-Shiong said that GPS Cancer test revenues rose threefold year over year during Q4, and 606 GPS tests were ordered, up from 325 a year ago.
The company has also developed two liquid biopsy cancer test, Liquid GPS Core for DNA and Liquid GPS Expression for RNA.
UCSF researchers will use NantHealth's GPS Cancer molecular analysis test in their molecular profiling study of metastatic breast cancer.
The company fell short of the consensus Wall Street revenue estimate, while its net loss for the quarter also widened.
Politico examines sales of Patrick Soon-Shiong's genetic test to institutions with clinicians with ties to his companies.
Asia Genomics will distribute NantHealth's cancer molecular profiling service in Singapore, Malaysia, Thailand, Vietnam, and the Philippines.
Hundreds of scientists have signed a letter criticizing the open-access Plan S, ScienceInsider reports.
NPR speaks with Rep. Eddie Bernice Johnson (D-Texas) about the US House of Representatives science committee.
A start-up company aiming to match cancer patients to treatments closes after about six weeks, Stat News reports.
In PLOS this week: somatic mutation associations unearthed in thousands of cancer exomes, pathogen detection assay, and more.